Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction
The AKR1B10 (aldo-keto reductase family 1 member B10) gene has important functions in carcinogen-induced neoplasia. AKR1B10 is also expressed in type 2 reaction leprosy patients (R2). We measured the expression of AKR1B10 in the skin lesions of patients with leprosy by immunohistochemistry from biop...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2018.00263/full |
| _version_ | 1818040962156331008 |
|---|---|
| author | Cleverson T. Soares Luciana R. V. Fachin Ana P. F. Trombone Patricia S. Rosa Cássio C. Ghidella Andrea F. F. Belone |
| author_facet | Cleverson T. Soares Luciana R. V. Fachin Ana P. F. Trombone Patricia S. Rosa Cássio C. Ghidella Andrea F. F. Belone |
| author_sort | Cleverson T. Soares |
| collection | DOAJ |
| description | The AKR1B10 (aldo-keto reductase family 1 member B10) gene has important functions in carcinogen-induced neoplasia. AKR1B10 is also expressed in type 2 reaction leprosy patients (R2). We measured the expression of AKR1B10 in the skin lesions of patients with leprosy by immunohistochemistry from biopsies that encompassed the spectrum of types of leprosy, based on the Ridley and Jopling classification [10 samples each of tuberculoid (TT), borderline tuberculoid (BT), mid-borderline (BB), and borderline lepromatous (BL) lesions; four samples of lepromatous lesions (LL)], reactional leprosy [14 samples of type 1 Reaction (R1) and 10 samples of type 2 Reaction (R2)], and biopsies from 9 healthy control (HC) subjects. In addition, 46 lepromatous lesions (BL and LL), 45 lepromatous lesions in regression, and 115 R2 lesions were included. Eight of 10 R2 samples (80%), 3 of 46 active BL and LL samples (6%), 23 of 45 BL and LL samples in regression (51%), and 107 of 115 R2 samples (93%) were positive for AKR1B10, differing significantly between all groups (p < 0.05). AKR1B10 expression was highest in the cytoplasm of macrophages. Thus, AKR1B10 is overexpressed on the lepromatous side (BL and LL) in samples that are in regression, especially type 2 reaction-associated lesions, rendering it a potential marker of type 2 reactional episodes of leprosy and a target of drugs against reactional episodes. |
| first_indexed | 2024-12-10T08:22:51Z |
| format | Article |
| id | doaj.art-d55d938febd540cd87f09da3aaca57f0 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-10T08:22:51Z |
| publishDate | 2018-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-d55d938febd540cd87f09da3aaca57f02022-12-22T01:56:18ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2018-09-01510.3389/fmed.2018.00263372350Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy ReactionCleverson T. Soares0Luciana R. V. Fachin1Ana P. F. Trombone2Patricia S. Rosa3Cássio C. Ghidella4Andrea F. F. Belone5Department of Anatomic Pathology, Instituto Lauro de Souza Lima, Bauru, BrazilDepartment of Anatomic Pathology, Instituto Lauro de Souza Lima, Bauru, BrazilDepartment of Health Science, Universidade do Sagrado Coração, Bauru, BrazilDivision of Research and Education, Instituto Lauro de Souza Lima, Bauru, BrazilAmbulatory of Leprosy, Jardim Guanabara Health Center, Rondonópolis, BrazilDepartment of Anatomic Pathology, Instituto Lauro de Souza Lima, Bauru, BrazilThe AKR1B10 (aldo-keto reductase family 1 member B10) gene has important functions in carcinogen-induced neoplasia. AKR1B10 is also expressed in type 2 reaction leprosy patients (R2). We measured the expression of AKR1B10 in the skin lesions of patients with leprosy by immunohistochemistry from biopsies that encompassed the spectrum of types of leprosy, based on the Ridley and Jopling classification [10 samples each of tuberculoid (TT), borderline tuberculoid (BT), mid-borderline (BB), and borderline lepromatous (BL) lesions; four samples of lepromatous lesions (LL)], reactional leprosy [14 samples of type 1 Reaction (R1) and 10 samples of type 2 Reaction (R2)], and biopsies from 9 healthy control (HC) subjects. In addition, 46 lepromatous lesions (BL and LL), 45 lepromatous lesions in regression, and 115 R2 lesions were included. Eight of 10 R2 samples (80%), 3 of 46 active BL and LL samples (6%), 23 of 45 BL and LL samples in regression (51%), and 107 of 115 R2 samples (93%) were positive for AKR1B10, differing significantly between all groups (p < 0.05). AKR1B10 expression was highest in the cytoplasm of macrophages. Thus, AKR1B10 is overexpressed on the lepromatous side (BL and LL) in samples that are in regression, especially type 2 reaction-associated lesions, rendering it a potential marker of type 2 reactional episodes of leprosy and a target of drugs against reactional episodes.https://www.frontiersin.org/article/10.3389/fmed.2018.00263/fullleprosyreaction type 2AKR1B10biomarkertherapeutic target |
| spellingShingle | Cleverson T. Soares Luciana R. V. Fachin Ana P. F. Trombone Patricia S. Rosa Cássio C. Ghidella Andrea F. F. Belone Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction Frontiers in Medicine leprosy reaction type 2 AKR1B10 biomarker therapeutic target |
| title | Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction |
| title_full | Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction |
| title_fullStr | Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction |
| title_full_unstemmed | Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction |
| title_short | Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction |
| title_sort | potential of akr1b10 as a biomarker and therapeutic target in type 2 leprosy reaction |
| topic | leprosy reaction type 2 AKR1B10 biomarker therapeutic target |
| url | https://www.frontiersin.org/article/10.3389/fmed.2018.00263/full |
| work_keys_str_mv | AT cleversontsoares potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction AT lucianarvfachin potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction AT anapftrombone potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction AT patriciasrosa potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction AT cassiocghidella potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction AT andreaffbelone potentialofakr1b10asabiomarkerandtherapeutictargetintype2leprosyreaction |